VitalStone Financial’s Definium Therapeutics DFTX Stock Holding History

VitalStone Financial’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-350	Closed	–	–	990
2023 Q1	$0	Buy	+350	New	+$1.16K	﹤0.01%	449

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

VitalStone Financial's DFTX Position: Q2 2023 in Review

VitalStone Financial sold out of Definium Therapeutics (DFTX) in Q2 2023, closing a stake of 350 shares.

VitalStone Financial first reported a position in DFTX in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 84 funds tracked by Wall St. Rank hold DFTX as of Q2 2023.

VitalStone Financial reported no remaining Definium Therapeutics position as of Q2 2023 after selling out during the quarter.
VitalStone Financial sold 350 Definium Therapeutics shares in Q2 2023.
VitalStone Financial first reported a position in Definium Therapeutics in Q1 2023 and held it in 1 quarter.
VitalStone Financial's Definium Therapeutics position peaked at $0 in Q1 2023.
84 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2023.

Based on VitalStone Financial's 13F filing for Q2 2023, filed 21 Aug 2023.